Nanobiotix has appointmented Alain Dostie, a senior executive from the pharmaceutical industry, as its Chief Operating Officer (COO).
Dostie will lead Nanobiotix’s operations, including development, manufacturing, market access and sales, for the Company’s lead product NBTXR3, which could obtain a CE Mark approval in 2017. Previously, Dostie was the Oncology General Manager at Novartis Germany. He joins Nanobiotix with over 25 years of international experience in the pharmaceutical industry, particularly in market access and oncology.
Commenting on his new appointment, new Nanobiotix’s COO said: “Nanobiotix is at the tipping point of its value creation with the coming first Phase II/III interim readout and a potential first market approval this year. The unique, unrivaled and broadly applicable technology developed by Nanobiotix, along with the strong and enthusiastic team, attracted me to the Company. I am very excited to join the Company at such an important time and contribute to its long-term success.”